| Abstract | OBJECTIVE: The aim of this study was to assess long-term effects for women following the use of magnesium sulphate for pre-eclampsia. DESIGN: Assessment at 2-3 years after delivery for women recruited to the Magpie Trial (recruitment in 1998-2001, ISRCTN 86938761), which compared magnesium sulphate with placebo for pre-eclampsia. SETTING: Follow up after discharge from hospital at 125 centres in 19 countries across five continents. POPULATION: A total of 7927 women were randomised at the follow-up centres. Of these women, 2544 were not included for logistic reasons and 601 excluded (109 at a centre where <20% of women were contacted, 466 discharged without a surviving child and 26 opted out). Therefore, 4782 women were selected for follow-up, of whom 3375 (71%) were traced. METHODS: Questionnaire assessment was administered largely by post or in a dedicated clinic. Interview assessment of selected women was performed. Main outcome measures Death or serious morbidity potentially related to pre-eclampsia at follow up, other morbidity and use of health service resources. RESULTS: Median time from delivery to follow up was 26 months (interquartile range 19-36). Fifty-eight of 1650 (3.5%) women allocated magnesium sulphate died or had serious morbidity potentially related to pre-eclampsia compared with 72 of 1725 (4.2%) women allocated placebo (relative risk 0.84, 95% CI 0.60-1.18). CONCLUSIONS: The reduction in the risk of eclampsia following prophylaxis with magnesium sulphate was not associated with an excess of death or disability for the women after 2 years. |
| Authors | Magpie Trial Follow-Up Study Collaborative Group
(Affiliation: lelia.duley at ndm.ox.ac.uk)
|
| Journal | BJOG : an international journal of obstetrics and gynaecology
(BJOG)
Vol. 114
Issue 3
Pg. 300-9
(Mar 2007)
ISSN: 1470-0328 England |
| PMID | 17166220
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
| Chemical References |
- Anticonvulsants
- Magnesium Sulfate
|
| Topics |
- Anticonvulsants
(therapeutic use)
- Child
- Female
- Follow-Up Studies
- Humans
- Magnesium Sulfate
(therapeutic use)
- Maternal Health Services
(utilization)
- Maternal Mortality
- Patient Acceptance of Health Care
(statistics & numerical data)
- Pre-Eclampsia
(drug therapy, mortality)
- Pregnancy
- Pregnancy Outcome
- Risk Factors
|
